Europe’s Medical Cannabis Sector Shows Steady Expansion

LOS ANGELES – Prohibition Partners’ report indicates that Europe’s medical Cannabis market could hit approximately €1.4 billion this year, driven by demand in key countries like Germany and the United Kingdom. Analysts point to a combination of policy shifts and patient growth as factors supporting this trajectory, though inconsistencies in national rules continue to temper overall progress.

Germany holds its position as the continent’s top market, with estimates placing its value at over €670 million for 2025 and potential to reach €1.32 billion by 2029. Recent reforms, including partial decriminalization earlier this year, have boosted patient numbers, now approaching 1.5 million. Imports surged to 36 tons in the first half of 2025, highlighting reliance on external suppliers amid domestic cultivation constraints. However, supply chain vulnerabilities, such as fluctuating import quality and bureaucratic delays, raise questions about sustainability without further investment in local production.

The United Kingdom ranks second, with market value expected to top €300 million this year and climb to €630 million by 2029. Patient counts have risen to more than 65,000 monthly, fueled by private clinics and telehealth services. Yet, the absence of public health system integration limits access for lower-income groups, potentially capping broader adoption unless reimbursement models evolve.

Poland emerges as the fourth-largest player, valued at €72 million in 2025. Telemedicine has played a key role in recovery from earlier regulatory setbacks, with prescriptions rebounding to over 44,000 per month by early this year. This growth underscores how digital tools can bridge gaps in traditional healthcare, but ongoing debates over online prescribing suggest risks of over-reliance on virtual platforms.

On the supply side, Portugal stands out with annual exports nearing 18 tons, nearly tripling from prior levels. Denmark follows with more than seven tons exported, while the Czech Republic has ramped up to 1.3 tons, mainly to Germany. These figures reflect a shift toward Europe as a production hub, reducing dependence on North American imports. Still, export-focused strategies in these nations often leave domestic markets underserved, prompting calls for balanced policies that address both trade and local needs.

In Switzerland, pilot programs involving over 10,000 participants are on track to generate nearly €24 million in sales by year-end. These trials, spanning major cities, offer data on controlled distribution that could inform wider reforms. Early results highlight benefits in public health monitoring, but challenges like varying canton-level approvals reveal the complexities of federal systems in scaling such initiatives.

Broader market forecasts vary, with some analysts predicting values of $6.75 billion for 2025, though Prohibition Partners’ more measured outlook aligns with observed trends. Critical examination shows that while patient access improves, disparities in regulation across borders hinder unified growth. For instance, export booms in smaller producers contrast with import-heavy consumers, creating potential bottlenecks if global supply chains face disruptions.

Here at Highly Capitalized Network, we note the data provided on Europe’s medical Cannabis sector indicates the build-up of a solid foundation. However, true progress requires harmonizing the rules and encouraging innovation. Failing to address these gaps puts the market at risk of uneven development that favors established players over emerging opportunities.